Defining ‘Psychedelic’: What a New Research Paper Proposes — and Why It Matters for Psilocybin Trials
Key Takeaways A new paper in the Journal of Psychopharmacology proposes explicit criteria for calling a compound "psychedelic," aiming to resolve long-standing...
What the First Psilocybin Brain-Imaging Trial for Bipolar Depression Is Actually Measuring
Key Takeaways NCT06506019 is a Phase 1 trial examining psilocybin's neurobiological effects in treatment-resistant bipolar II depression, a population historically excluded from psychedelic...
What Oncology Providers Actually Think About Psychedelic-Assisted Therapy: A New Study
Key Takeaways A new qualitative study published in the American Journal of Hospice and Palliative Medicine surveyed oncology providers about their readiness to incorporate psychedelic-assisted...
Crossover Trial Compares Acute Effects of Oral Psilocybin, Oral Psilocin, and Sublingual Psilocin
Key Takeaways A randomized crossover trial published in the Journal of Psychopharmacology compared three botanical formulations: oral psilocybin, oral psilocin, and sublingual psilocin. Sublingual...
Copyright © 2026 Divi. All Rights Reserved.